Chiral Se@CeO 2 superparticles for ameliorating Parkinson's disease.
Ximing LiuHongyu ZhangChanglong HaoHua KuangChuanlai XuLiguang XuPublished in: Nanoscale (2023)
In this study, we prepare chiral D-/L-type Se@CeO 2 superparticles (D-/L-SPs) with a g-factor of 0.018 using D-/L-cysteine as chiral ligands. The chiral SPs demonstrate ultra-high enzyme activity of peroxidase (POD), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx). Due to the synergistic effect between Se and CeO 2 , the maximum initial velocity of GPx, CAT, and POD for L-SP is 10, 7, and 5.6 times higher than that of a mixture of Se nanoparticles (NPs) and CeO 2 NPs. Significantly, the chiral L-SPs show much stronger ROS scavenging ability than D-SP in the PD-like cell model. Moreover, the amount of α-synuclein (α-syn) in the cerebrospinal fluid of PD mice is reduced by 70.7% within two weeks. The L-SPs effectively alleviate neurodegeneration in a mouse model of PD, showing potential applications in the clinical treatment of neurodegenerative diseases.
Keyphrases
- capillary electrophoresis
- ionic liquid
- hydrogen peroxide
- mouse model
- cerebrospinal fluid
- mass spectrometry
- dna damage
- cell death
- single cell
- high resolution
- cell therapy
- type diabetes
- nitric oxide
- reactive oxygen species
- metabolic syndrome
- risk assessment
- amyotrophic lateral sclerosis
- blood flow
- fluorescent probe
- single molecule
- wild type